organization · Reporting owner
Horowitz Limited Partnership VIII
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tarsus Pharmaceuticals, Inc.
Report date October 20, 2020 · Filed October 20, 2020
Section 16 reporting ended · disclosed 2020-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,920,933 |
Ending reported balance
After 2020-10-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-10-20 · Conversion · Acquired 1,434,790 · Balance 1,434,790 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Row 2 · 2020-10-20 · Conversion · Acquired 245,966 · Balance 1,680,756 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Row 3 · 2020-10-20 · Conversion · Acquired 71,427 · Balance 1,752,183 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Row 4 · 2020-10-20 · Purchase · Acquired 168,750 · Balance 1,920,933 |
| Common StockSEC Table I · non-derivative | IndirectBy the Adam S. Horowitz Revocable Trust | 66,172 |
Last balance in matching sequence
After 2020-10-20 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 5 · 2020-10-20 · Conversion · Acquired 43,151 · Balance 43,151 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. Row 6 · 2020-10-20 · Conversion · Acquired 7,396 · Balance 50,547 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. Row 7 · 2020-10-20 · Purchase · Acquired 15,625 · Balance 66,172 F2: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-20 · Conversion · Disposed 1,434,790 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-20 · Conversion · Disposed 245,966 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-20 · Conversion · Disposed 71,427 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy the Adam S. Horowitz Revocable Trust | 0 |
Reported balance
After 2020-10-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-10-20 · Conversion · Disposed 43,151 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy the Adam S. Horowitz Revocable Trust | 0 |
Reported balance
After 2020-10-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-10-20 · Conversion · Disposed 7,396 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.
F2: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries B Preferred Stock · Derivative | 7,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 12 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Adam S. Horowitz Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 7,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries A Preferred Stock · Derivative | 43,151 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 11 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Adam S. Horowitz Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 43,151 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries C Preferred Stock · Derivative | 71,427 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 10 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries B Preferred Stock · Derivative | 245,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 9 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 245,966 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries A Preferred Stock · Derivative | 1,434,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 8 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,434,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | PurchaseCommon Stock | 15,625 | $16.00 | $250,000.00 |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 7 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Adam S. Horowitz Revocable Trust Disclosed balance after: 66,172 F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 7,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 6 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Adam S. Horowitz Revocable Trust Disclosed balance after: 50,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 43,151 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 5 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Adam S. Horowitz Revocable Trust Disclosed balance after: 43,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | PurchaseCommon Stock | 168,750 | $16.00 | $2,700,000.00 |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 4 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920,933 Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 71,427 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 3 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,752,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 245,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 2 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 19:59 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 1,434,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 1 Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.